Menu

Blog Posts

Congressional Committee Lineups Still in Flux After McCarthy Installed as House Speaker

In Federal, Legislative151 Views Tom Mirga
Kevin McCarthy
U.S. Rep. Kevin McCarthy (R-Calif.) takes the podium Jan. 7 after being elected as House Speaker.

The members, GOP chairs, and top-ranking Democrats of U.S. House committees for the 118th Congress still had not been formally announced this morning, three days after Republicans chose Rep. Kevin McCarthy (R-Calif.) to be House speaker.

It took

…
Read More »

CMS Plans in April to Address Potential Remedies for Illegal Drug Payment Cuts for 340B Hospitals

In Federal, Regulatory431 Views Tom Mirga
Agenda
CMS plans to issue a proposed rule in April regarding “potential remedies” for illegal Part B drug payment cuts for 340B hospitals from 2018 through late September 2022.

Federal Medicare officials plan to issue a proposed rule in April regarding “potential remedies” for illegal Part B drug payment cuts for 340B hospitals from 2018 through late September 2022.

The Centers for Medicare & Medicaid Services revealed

…
Read More »

340B Provider Ally Stabenow Will Not Seek Re-Election to U.S. Senate in 2024

In Federal, Legislative190 Views Tom Mirga
Debbie Stabenow
U.S. Sen. Debbie Stabenow (D-Mich.) will not seek re-election in 2024, depriving 340B covered entities of a reliable ally.

U.S. Sen. Debbie Stabenow (D-Mich.) will not seek re-election in 2024, a decision that will deprive 340B covered entities of a reliable ally in Congress.

Stabenow issued a statement yesterday announcing her decision. She was one of six senators—three

…
Read More »

340B Pricing: Navigating Pharmacy Discount Programs to Benefit Your Entity & Patients

In Sponsored Content595 Views Sponsored Content
Jim Donnelly, Hudson Headwaters 340B
How to Address Challenges in Providing Discounts Directly at the Pharmacy Counter

SPONSORED CONTENT

The 340B statute was written as a drug pricing program that outlines specifically what manufacturers are required to charge qualified covered entities for their drugs based on a defined formula. The intent of the 340B program is to help these safety net entities stretch their scarce resources to maintain and

…
Read More »

Janssen Providing Refunds for 340B Overcharges During Q1 2020

In Federal, Pharma Industry, Regulatory178 Views Tom Mirga
Janssen
Janssen Pharmaceuticals is providing refunds to 340B covered entities for overcharges on 14 NDCs during Q1 2020.

Johnson & Johnson’s Janssen Pharmaceuticals division is providing refunds to 340B covered entities for overcharges on 14 NDCs during Q1 2020.

The U.S. Health Resources and Services Administration (HRSA) posted J&J’s refund notice yesterday. The company said

…
Read More »

Lilly Says 340B Entities Can’t Designate Central Fill Pharmacies as Contract Pharmacies

In Pharma Industry1395 Views Tom Mirga
Lilly
Lilly updated its restrictions on 340B pricing to disallow covered entities from designating central fill pharmacies as contract pharmacies.

Drug manufacturer Eli Lilly late last month again updated its conditions on 340B pricing when covered entities use contract pharmacies.

Lilly was the first company to impose such conditions, starting with one drug in July 2020 then

…
Read More »

PhRMA Takes its Fight Against Arkansas 340B Law to Federal Appeals Court

In Federal, Judicial365 Views Tom Mirga
U.S. Eighth Circuit Court of Appeals
PhRMA has asked the federal appeals court in St. Louis to overturn a lower court's ruling that federal law does not preempt Arkansas’s novel 340B anti-discrimination law.

Brand drug manufacturers have asked a federal appeals court to overturn a judge’s ruling last month that Arkansas’s novel 340B anti-discrimination law is not preempted by the 340B statute nor by the U.S. Food and Drug Administration’s Risk

…
Read More »

Alcon Providing Refunds for 340B Overcharges on 22 Products

In Federal, Pharma Industry, Regulatory170 Views Tom Mirga
Alcon
Alcon is providing refunds for charges above 340B ceiling prices on 22 NDCs for varying sales periods from Q3 2019 through Q3 2022.

Swiss eye care drug manufacturer Alcon is providing refunds for charges above 340B ceiling prices on 22 NDCs for varying sales periods from Q3 2019 through Q3 2022.

The U.S. Health Resources and Services Administration posted Alcon’s public

…
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer